

NOVAMED SOLUTIONS SALES PERFORMANCE DASHBOARD

Ranking Option

10

Country

All

Year

All

Value

Bottom

Top

Top/Bottom Analysis

Top/Bottom Analysis 2

Customer Analysis 1

Customer Analysis 2

Revenue

\$71.31M

Quantity Sold

269.47K

COGS

\$12.85M

Profit

\$58.45M


Profit Margin

81.97%


Top | Bottom Drug Analysis by Revenue

Drug Name	Revenue	Ranking Revenue
Doxycycline	\$3,532,158	\$3,532,158
Ergocalciferol	\$3,481,793	\$3,481,793
Lisinopril	\$3,453,483	\$3,453,483
Clonazepam	\$3,108,232	\$3,108,232
Ezetimibe	\$3,029,652	\$3,029,652
Valacyclovir	\$2,813,744	\$2,813,744
Albuterol	\$2,791,058	\$2,791,058
Sertraline	\$2,734,339	\$2,734,339
Levothyroxine	\$2,705,289	\$2,705,289
Simvastatin	\$2,638,042	\$2,638,042

Quantity Sold (%) by Top 5 Drug



Revenue || by Month Analysis



NOVAMED SOLUTIONS SALES PERFORMANCE DASHBOARD

Ranking Option

10

Country

All

Year

All

Value

Bottom


Top

Top/Bottom Analysis

Top/Bottom Analysis 2



Customer Analysis 1

Customer Analysis 2



Top | Bottom Drug Analysis by Profit

DrugName	Profit	Ranking Profit
Doxycycline	\$3,359,227	\$3,359,227
Ergocalciferol	\$3,202,154	\$3,202,154
Lisinopril	\$3,112,124	\$3,112,124
Simvastatin	\$2,507,072	\$2,507,072
Clonazepam	\$2,490,301	\$2,490,301
Ezetimibe	\$2,457,750	\$2,457,750
Insulin Glargine	\$2,432,600	\$2,432,600
Sertraline	\$2,388,923	\$2,388,923
Levothyroxine	\$2,229,772	\$2,229,772
Aspirin	\$2,175,041	\$2,175,041



NOVAMED SOLUTIONS SALES PERFORMANCE DASHBOARD

Year ▼

All ▼

Country ▼

All ▼

Buyer Type ▼

All ▼

Drug Name ▼

All ▼

Top/Bottom Analysis

Top/Bottom Analysis 2

Customer Analysis 1

Customer Analysis 2

Revenue



\$71.31M

Total Customers



200

COGS



\$12.85M

Profit



\$58.45M

Profit Margin



81.97%

Avg. Rev. Analysis | Age Range | Age Group | Buyer Type

BuyerType	Adult	Aged	Middle-Aged	Young Adult
<div><div></div>Seller</div>				
29–39	\$327,509			
18–28				\$315,285
40–59			\$311,151	
60+		\$309,973		
<div><div></div>User</div>				
40–59			\$43,642	
60+		\$41,965		
18–28				\$41,651
29–39	\$40,353			

Revenue by Country




Top 5 Performing Customers

Full Name	Revenue	Profit	Qty Sold
David Johnson	\$3,943,315	\$3,236,305	14,494
Bob Williams	\$3,727,469	\$3,035,553	13,939
Bob Smith	\$3,276,114	\$2,605,175	13,487
Jane Brown	\$3,309,477	\$2,668,118	12,607
Alice Smith	\$3,121,059	\$2,588,146	11,305

Bottom 5 Performing Customers

Full Name	Revenue	Profit	Qty Sold
Alice Brown	\$1,629,109	\$1,309,575	6,525
Alice Williams	\$1,547,364	\$1,291,870	5,837
Carol Jones	\$903,938	\$737,999	3,186
Jane Smith	\$606,666	\$497,246	1,878
Carol Smith	\$274,432	\$234,483	1,196

Gender Customer Base



NOVAMED SOLUTIONS SALES PERFORMANCE DASHBOARD

Year ▼

All ▼

Country ▼

All ▼

Drug Name ▼

All ▼

Buyer Type ▼

All ▼

Top/Bottom Analysis

Top/Bottom Analysis 2

Customer Analysis 1

Customer Analysis 2

Revenue



\$71.31M

Total Customers



200

COGS



\$12.85M

Profit



\$58.45M

Profit Margin




81.97%


Revenue by Country and Customer Type

Customer Type	Revenue	Country
Seller	\$28,111,483	Canada
Seller	\$13,217,985	Australia
Seller	\$5,907,211	Germany
Seller	\$5,898,630	United Kingdom
Seller	\$4,886,782	United States
Seller	\$4,834,431	France

Age Distribution || Customer Base



Country || Customer Base Analysis



Buyer Type | Gender | Age Distribution

Buyer Type	Female	Male	Other
<input checked="" type="checkbox"/> Seller			
Adult	10	18	8
Aged	24	32	7
Middle-Aged	26	30	18
Young Adult	5	14	8
<input checked="" type="checkbox"/> User			
Adult	10	18	8
Aged	24	32	7
Middle-Aged	26	30	18
Young Adult	5	14	8

Revenue Analysis || Age-Group || Gender

